Teva Pharmaceutical Industries Ltd. (NYSE: Tifa;; level: Tiva) The cliff bulletin with the US Securities and Stock Exchange Committee (SEC), which will allow it to issue a variety of securities, including the US Wadih shares (ADSS), debt papers, purchase contracts, and units. The release bulletin at this stage of the company does not require the proceeding already in the offer, but if the money is used for public work purposes, worker capital and debt payment.
Related articles
Analysts remain positive in Teva
Teva is sharply located on the directives of 2025 disappointing
TEVA share price at the highest level in 6 years after the results of the experiment
As of the end of 2024, TeVA debts amounted to $ 17.8 billion, a decrease from 19.8 billion dollars at the end of 2023, due to the payment of debts of $ 1.6 billion and exchange rate fluctuations that had a positive impact on debt. The net debt was $ 14.5 billion. TEVA has benefited from the upgrade of debt assessments by the main classification agencies.
TEVA has not raised the capital since it acquired Actavis from Allergan in 2016 – a deal worth about $ 40 billion that mainly raised the debt, which the company later immersed in CRISIS.
In 2025, TEVA faces the payment of debts, which total $ 1.8 billion (some in the Swiss and the euro), and in 2026-2027, debt payment is higher, reaching $ 3.4 billion and $ 2.9 billion, respectively.
TEVA, led by CEO Richard Francis, is trading on Tase and NYSE with the maximum market for $ 19.8 billion.
It was published by Globes, Israel Business News – En.globes.co.il – on February 9, 2025.
© Copy Publish Publisher Itonut (1983) Ltd. , 2025.
Comments are closed, but trackbacks and pingbacks are open.